Related Experiment Video

Updated: Jul 9, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

333

Targeting long non-coding RNAs in cancer therapy using CRISPR-Cas9 technology: A novel paradigm for precision

Rahul Kumar Mahato1, Srinjan Bhattacharya1, Naina Khullar2

  • 1Laboratory of Translational Medicine and Nanotherapeutics, Department of Human Genetics and Molecular Medicine, School of Health Sciences, Central University of Punjab, Bathinda, India.

Journal of Biotechnology
|December 8, 2023
PubMed

Insights

CRISPR-Cas9 technology offers a novel approach to target long non-coding RNAs (lncRNAs) for cancer therapy. This strategy holds promise for developing personalized cancer treatments and overcoming drug resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • Cancer remains a leading cause of death globally, necessitating novel diagnostic and therapeutic strategies.
  • Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in cancer development and progression.
  • Identifying new molecular targets and biomarkers is crucial for advancing cancer patient care.

Purpose of the Study:

  • To explore the application of CRISPR-Cas9 gene-editing technology for targeting lncRNAs in cancer.
  • To review the potential of lncRNA targeting as a therapeutic strategy for cancer management.
  • To discuss the integration of CRISPR-Cas9 and lncRNA research for personalized cancer therapies.

Main Methods:

  • Review of current literature on CRISPR-Cas9 technology and its application in lncRNA research.
  • Discussion of CRISPR-Cas9-mediated targeting strategies for lncRNAs, including interference, activation, and knockout.
  • Exploration of combining CRISPR-Cas9 with high-throughput functional genomics to identify critical lncRNAs.

Main Results:

  • CRISPR-Cas9 provides a versatile platform for precise targeting of lncRNAs.
  • CRISPR-Cas9 enables the identification of lncRNAs essential for specific cancer subtype survival.
  • Synergistic approaches combining CRISPR-Cas9-mediated lncRNA targeting with other therapies can overcome drug resistance.

Conclusions:

  • CRISPR-Cas9-mediated lncRNA targeting represents a promising avenue for innovative cancer therapeutics.
  • This approach facilitates the development of tailored treatments and personalized cancer therapies.
  • The integration of lncRNA research and CRISPR-Cas9 technology offers significant potential for improving cancer treatment outcomes.
Keywords:
CRISPR interferenceCRISPR-Cas9Cancer therapeuticsGene editingLong non-coding RNAs

More Related Videos

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR13:04

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR

Published on: March 1, 2019

8.9K
CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis10:40

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

2.4K

Related Concept Videos

CRISPR01:59

CRISPR

Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
51.6K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
CRISPR and crRNAs02:53

CRISPR and crRNAs

Bacteria and archaea are susceptible to viral infections just like eukaryotes; therefore, they have developed a unique adaptive immune system to protect themselves. Clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins (CRISPR-Cas) are present in more than 45% of known bacteria and 90% of known archaea.
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
17.0K